Background: The disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) vary in their mode of action and when therapies are changed, the consequences on inflammatory and degenerative processes are largely unknown. Objective: We investigated the effect of switching from other DMTs to fingolimod on cerebrospinal fluid (CSF) biomarkers. Methods: 43 RRMS patients were followed up after 4-12 months of fingolimod treatment. Concentrations of C-X-C motif chemokine 13 (CXCL13), chemokine (C-C motif) ligand 2 (CCL2), chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light protein (NFL), and neurogranin (NGRN) were analyzed by enzyme-linked immunosorbent assay (ELISA), while chitotriosidase (CHIT1) was analyzed by spectrofluorometry. Results: The levels of NFL, CXCL13, and CHI3L1 decreased (p < 0.05) after fingolimod treatment. Subgroup analysis revealed a reduction in NFL (p < 0.001), CXCL13 (p = 0.001), CHI3L1 (p < 0.001), and CHIT1 (p = 0.002) in patients previously treated with first-line therapies. In contrast, the levels of all analyzed biomarkers were essentially unchanged in patients switching from natalizumab. Conclusion: We found reduced inflammatory activity (CXCL13, CHI3L1, and CHIT1) and reduced axonal damage (NFL) in patients switching from first-line DMTs to fingolimod. Biomarker levels in patients switching from natalizumab indicate similar effects on inflammatory and degenerative processes. The CSF biomarkers provide an additional measure of treatment efficacy.
Introduction
Fingolimod is an inverse agonist for sphingosine-1-phosphate receptors, which reduce the number of circulating memory T cells and their infiltration of the central nervous system (CNS), 1 and it may also influence regeneration of damaged CNS parenchyma. 2 Fingolimod is mostly used as a second-line diseasemodifying therapy (DMT) in patients with relapsingremitting multiple sclerosis (RRMS). In two randomized clinical phase III trials (randomized controlled trial (RCT)), fingolimod reduced the relapse rate and lesion formation compared with placebo (FREEDOMS 3 and FREEDOMS II 4 ), and based on these outcomes, it was superior to interferon beta 1a (TRANSFORMS 5 ).
Previous investigations of cerebrospinal fluid (CSF) biomarkers revealed altered profiles of immune cells and the proteins that reflect different aspects of the immunopathogenesis of MS. We have demonstrated that natalizumab treatment of RRMS reduced the CSF level of the neurofilament light protein (NFL) to levels found in healthy controls (HCs). 6 Recently, fingolimod showed similar effects on axonal damage in a subgroup of patients participating in one of the pivotal RCTs for this treatment. 3, 7 In these patients, the reduction of the CSF NFL level correlated with improvements in relapse and magnetic resonance imaging (MRI) findings. 7 In this study, we investigated the concentration of biomarkers in the CSF from RRMS patients who switched to fingolimod from first-line therapies (interferon beta, glatiramer acetate, and teriflunomide) because of breakthrough disease activity or second-line therapy (natalizumab) to reduce the risk of progressive multifocal leukoencephalopathy (PML) in patients positive for the John Cunningham (JC) virus. We used biomarkers that reflect leukocyte trafficking: C-X-C motif chemokine 13 (CXCL13), chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1); microglial activation: chitinase-3-like protein 1 (CHI3L1, also known as YKL-40) and chitotriosidase (also known as chitinase 1, CHIT1); axonal degeneration: NFL; synaptic degeneration: neurogranin (NGRN); and astrocytic reaction: glial fibrillary acidic protein (GFAP).
Except for NGRN, all these biomarkers have previously been associated with disease activity [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] or progression 11, 12, 18 in MS, and DMTs have reduced the CSF levels of NFL, 6,15 CHI3L1, 19 CHIT1, 20 and CXCL13. 21 A better understanding of these biomarkers and their response to DMTs could lead to their implementation in clinical practice and treatment monitoring.
Material and methods

Patients and HC subjects
Patients with RRMS fulfilling the revised McDonald criteria 22 were consecutively enrolled in the study at the MS centers of Sahlgrenska University Hospital, Gothenburg (n = 17) and Karolinska University Hospital, Stockholm, Sweden (n = 26). In total, 43 patients were included, three treatment naive and 40 patients switching from another DMT. Treatment with oral fingolimod, 0.5 mg once daily, started at baseline. Patients were prospectively followed and had a second assessment, including lumbar puncture after 4 (n = 4), 6 (n = 18), 9 (n = 3), or 12 (n = 18) months. According to their previous treatment, these patients were divided into first-line (n = 26, interferon beta, glatiramer acetate, and teriflunomide) and second-line treatment groups (n = 14, natalizumab). The reasons for switching to fingolimod from first-line treatments were evidence of breakthrough disease (n = 23), insufficient compliance (n = 1), and undocumented (n = 2). All the second-line-treated patients were serum positive for the JC virus antibody (JCV+) and had been on natalizumab treatment for 25 months or more and switched because of the increased risk for PML. The median wash-out period before starting fingolimod treatment was 22 days (range = 0-1107 days; four patients had a treatment interruption for >1 year) for the first-linetreated patients and 81 days (range = 42-134 days) for second-line-treated patients. Thirty-nine blood donors and university students served as age-matched HC. None of them had any neurological signs or a history of neurological disease. Demographic and clinical characteristics of the cohorts of patients and HC are presented in Table 1 .
Clinical assessments and MRI
Patients underwent a clinical neurological examination, MRI scanning, and lumbar puncture at baseline and after 4-12 months of fingolimod treatment. A relapse was defined according to McDonald criteria as an episode of neurological disturbance lasting for at least 24 hours. 23 The neurological examinations were performed by trained neurologists and disability was measured using the Expanded Disability Status Scale (EDSS) 24 and disease severity with the Multiple Sclerosis Severity Score (MSSS). 25 The MRI scans of the brain and cervical column were performed with 1.5 or 3.0 Tesla machines using a 3-mm slice thickness, and in close association with the clinical neurological examinations and lumbar puncture (median 44 days, range: 0-379 days). In each patient, the baseline MRI scan was compared with the previous MRI scan (median interval 549 days, range: 101-936 days). The treatment was not changed between the MRI scans, that is, patients remained on either first-line or second-line treatment.
A standard protocol for MS was applied with T1-and T2-weighted sequences, fluid-attenuated inversionrecovery (FLAIR), and T1 following a standard dose of intravenous gadolinium (Gd) contrast. New disease activity on MRI was defined as a new Gd-enhanced lesion or a new or enlarged T2 lesion.
Blood tests and CSF sampling
Peripheral blood and CSF were sampled at the clinical assessment. The CSF samples were handled according to the consensus protocol of the BioMS-EU network for CSF biomarker research in MS. 26 Disease activity (relapse, contrast enhancing, and new or enlarged lesion) was recorded at baseline and at follow-up (Table 2) . At follow-up, none of patients had relapse prior to lumbar puncture.
Biomarker analysis
All analyses were performed by board-certified laboratory technicians at the Clinical Neurochemistry Laboratory, at the Sahlgrenska University Hospital, according to protocols approved by the Swedish Board for Accreditation and Conformity Assessment. The NFL protein was measured with a sensitive sandwich enzyme-linked immunosorbent assay (ELISA) method (NF-light ® ELISA kit; UmanDiagnostics AB, Umeå, Sweden). Intra-and inter-assay coefficients of variation were below 10%. The lower limit of quantification (LLoQ) of the assay was 31 pg/mL. The GFAP was measured by ELISA, as previously described. 27 Briefly, ELISA plates were coated with hen anti-GFAP IgG followed by incubation with CSF samples for 2 hours, and then rabbit anti-GFAP IgG was added as a secondary antibody and incubated for 1 hour, both at room temperature. Detection was performed with peroxidase-conjugated donkey anti-rabbit IgG and 3,3′,5,5′-tetramethylbenzidine substrate. The absorbance was read at λ 490 nm, and the sensitivity of the GFAP assay was 16 pg/mL. The CXCL13 was measured by ELISA (Human CXCL13/BLC/BCA-1 Immunoassay; R&D Systems Inc., Abingdon, UK), according to the manufacturer's instructions. The average intra-and inter-assay coefficients of variation were ⩽10% and the LLoQ was 7.8 pg/mL. The CHI3L1 was analyzed with solid phase sandwich ELISA (Human Chitinase 3-like 1 Quantikine ELISA Kit; R&D Systems Inc., Minneapolis, MN, USA). The intra-assay coefficient of variation was below 7% and the LLoQ was 8.15 pg/mL. The CCL2 was analyzed by solid phase sandwich ELISA (Human CCL2/ MCP-1 Quantikine ELISA Kit; R&D Systems Inc., Minneapolis, MN). Intra-and inter-assay coefficients 
Ethics
All patients and HC voluntarily participated in the study and informed consent was obtained from all subjects. The regional ethical review boards in Uppsala, Sweden (Dnr 2005:253) and Stockholm (Dnr 2009:2107) approved the study.
Results
Biomarker concentrations after fingolimod treatment
The patients who were followed up after 4-12 months of fingolimod treatment (n = 43) had significantly reduced CSF levels of NFL, CXCL13, and CHI3L1 compared with their baseline. The mean pre-treatment level of NFL, 1183 pg/mL (standard deviation (SD) = 2 135), decreased to 654 pg/mL (SD = 448; p = 0.036) after treatment, the CXCL13 level decreased from 19.0 pg/mL (SD = 25.9) to 8.1 pg/mL (SD = 1.2; p = 0.001), and the CHI3L1 level decreased from 144 ng/mL (SD = 67) to 119 ng/mL (SD = 40; p < 0.001; Figures 1-3) . The mean post-treatment levels of NFL and CHI3L1 were significantly higher than in HC (p < 0.001 for both), whereas, the mean post-treatment level of CXCL13 was similar to that of HC (Figures 1-3) . The mean levels of CCL2 and GFAP did not significantly change prior to and after the treatment with fingolimod; in fact, both baseline and follow-up concentrations were similar to those of HC. Although patients had lower pre-and postfingolimod treatment levels of NGRN (p = 0.059 and p = 0.020, respectively) and higher levels of CHIT1 (p < 0.001 and p < 0.001, respectively) compared with HC, fingolimod did not influence their mean levels. The levels of NFL, GFAP, and CCL2 were detectable in all patients and HC. The levels of CXCL13 were below the LLoQ in 39 HC and 27 patients, the levels of CHIT1 were below the LLoQ in 12 HC and 6 patients, and the levels of NGRN were below the LLoQ in 14 HC and 20 patients.
The influence of previous DMT on biomarker concentrations
At baseline, patients previously treated with first-line therapies had significantly higher levels of NFL (p = 0.006), CXCL13 (p = 0.005), CHI3L1 (p = 0.025), and CHIT1 (p = 0.005) compared with those previously treated with natalizumab, a second-line therapy, whereas their NGRN levels were lower (p = 0.067). There was no difference in the pre-fingolimod treatment levels of GFAP and CCL2 between first-and second-line treatment groups. Fingolimod treatment decreased the levels of NFL, CXCL13, CHI3L1, and CHIT1 (p < 0.001, p = 0.001, p < 0.001, and p = 0.002, respectively) in patients who switched from first-line therapies. However, the levels of these biomarkers were still significantly higher after fingolimod treatment compared with controls (p < 0,001, p = 0.031, p < 0.001, and p < 0.001, respectively). In contrast, the levels of all analyzed biomarkers were essentially unchanged by fingolimod treatment in patients who switched from natalizumab treatment ( Table 2 and Figures 1-3 ). Only CHIT1 was significantly increased in patients treated with natalizumab compared with HC (p = 0.032).
The influence of fingolimod treatment duration on biomarker concentrations
Patients were dichotomized into those who had fingolimod treatment for less or more than 6 months. Subgroup analysis revealed that fingolimod treatment for 6 months or less reduced CSF levels of NFL (p = 0.002), CXCL13 (p = 0.012), and CHI3L1 (p = 0.001). There were no significant differences between biomarker levels from patients who were followed for up to 6 months and those who were followed for more than 6 months.
Clinical and radiological effects of fingolimod treatment
Prior to fingolimod treatment, patients on first-line treatments had more disease activity as determined by both clinical and radiological measures, than those on second-line treatment ( Table 3) . Within 3 months prior to switching to fingolimod, 5 patients on first-line treatment had a relapse and 10 patients displayed one or more Gd-enhanced lesion, while only 1 patient on second-line treatment had one or more Gd-enhanced lesion with no relapse. Prior to fingolimod treatment, most patients had new or enlarged T2 lesions probably due to long intervals between the previous and the baseline MRI scan. At follow-up and while treated with fingolimod, no patient experienced relapses in either group and one patient in each group displayed one or more Gd-enhanced lesion. The number of new T2 and Gd-enhancing lesions was decreased significantly in patients previously on first-line treatments (p = 0.007 and p = 0.001, respectively). In contrast, fingolimod had no significant effect on disability or disease severity during follow-up. The median pretreatment EDSS was 2.5 (0-6.5) in the group switching from first-line treatments and 3.25 (0-6.5) in the group on second-line treatment. The median posttreatment EDSS values were 2.5 (0-6.5) and 3.0 (0-6.5), respectively. 
Correlations between clinical and radiological outcomes and biomarkers
The decrease in the relapse rate correlated with the decrease in the CHI3L1 level (r = 0.491, p = 0.001) and decrease in Gd-enhanced and T2 lesions (r = 0.401, p = 0.010 and r = 0.329, p = 0.038, respectively). There was a lack of correlation between the biomarker levels and EDSS and MSSS. The decrease in Gd-enhanced lesions correlated with the CHI3L1, NFL, and CXCL13 levels (r = 0.409, p = 0.009; r = 0.396, p = 0.011; and r = 0.345, p = 0.029; respectively) and the decrease in T2 lesions correlated with the CHI3L1, NFL, and NGRN levels (r = 0.383, p = 0.015; r = 0.424, p = 0.008; and r = −0.341, p = 0.031; respectively). The interval between lumbar puncture and MRI was more than 4 months in six patients treated with first-line DMTs. However, correlations between MRI measures and CSF biomarker concentrations were not significantly influenced when removing these patients from the analysis. No significant differences in baseline biomarker concentrations were found between patients with Gd-enhancement and those without such activity.
Discussion
In this study, we demonstrated that fingolimod treatment reduced biomarker concentrations in CSF, reflecting reduced microglial activation (CHI3L1, CHIT1), B-cell activity (CXCL13), and axonal damage (NFL) in patients with RRMS. This effect was observed in patients previously treated with first-line therapies, and the majority of these patients switched to fingolimod because of breakthrough disease activity. In contrast, the biomarker levels were essentially stable in JCV+ patients previously treated with natalizumab. The switch to fingolimod in these patients was motivated entirely by being JCV+ and was a measure to reduce the risk of PML. In contrast to the former group, these patients were all clinically and radiologically stable before the switch. Thus, based on CSF biomarker concentrations, the influence of fingolimod on pathological processes of RRMS seemed to be superior to first-line therapies and equal to natalizumab.
However, even on fingolimod treatment, CHI3L1, CHIT1, CXCL13, and NFL concentrations did not reach the levels observed in age-matched HC. This is in contrast to previous reports on natalizumab treatment of RRMS patients that showed decreased NFL and CXCL13 levels compared with those observed in HC. 6, 21 In this study, we confirmed these biomarker levels in natalizumab-treated patients. Of the analyzed biomarkers, only CHIT1 was increased compared with HC in natalizumab-treated patients prior to switching to fingolimod. Thus, although the biomarker levels of patients previously treated with natalizumab did not increase significantly compared with baseline levels and generally remained at low levels after fingolimod treatment, the CHI3L1, CHIT1, and NFL levels were still significantly higher than those of HC. Fingolimod treatment reduced the relapse rate and formation of new lesions on MRI. Again, this effect was entirely attributed to the group of patients previously on first-line drugs. The measures of decreased disease activity correlated with the reduction in these biomarkers.
The marker GFAP indicates MS progression, correlates with EDSS and MSSS, 12, 18 and is believed to reflect astrogliosis. 18 Our result is in line with this assumption since no clinical neurological deterioration was observed and the GFAP level remained essentially unchanged. However, in previous studies, the highest correlation was confined to patients with progressive MS who had a mean follow-up of 9 years. 18 Thus, the selection of patients and the limited time of follow-up in this study might have influenced the results.
Astrocytes are the major CNS source of CCL2 in both experimental autoimmune encephalomyelitis and MS, 10, 17 but it is also produced by endothelial cells. 28 We could not show that fingolimod influenced the CCL2 level in CSF. In previous studies, CSF levels of CCL2 were lower in active MS, with a median EDSS of 5.0, 9, 16 but did not differ significantly in stable MS with a low EDSS (1.5-3.0) compared with controls. 16 The temporal decrease in CCL2 is related to clinical relapse onset and is increased thereafter (analyzed after 5 and 15 weeks). 29 Thus, the less disabled patients and CSF sampling essentially during clinically stable periods probably explain why CCL2 levels were not significantly different compared with HC.
In contrast to previous studies on MCI and AD, [30] [31] [32] NGRN levels were higher in HC than in RRMS patients and were not influenced by the fingolimod treatment.
In mild cognitive impairment (MCI) and Alzheimer's disease (AD), the dendritic spines are degenerated and the NGRN level increases and is correlated with cognitive decline. 32 We show for the first time that the NGRN concentration is decreased in RRMS, although the reason for this reduction is unknown. However, the mean CSF NGRN level was not significantly different between RRMS patients previously treated with firstcompared with second-line treatments, and fingolimod did not influence the level.
Owing to the non-randomized design of this study, we cannot rule out that reduced biomarker levels could be due to regression to the mean. However, this explanation seems less plausible, because of the magnitude of the biomarkers reduction. It should also be noted that treatment was not selected on the basis of biomarker levels, which therefore should not have contributed to a selection bias regarding those parameters. Furthermore, the treatment duration and length of wash-out periods may have influenced biomarker levels at baseline. However, the mean wash-out period was longer in the group on second-line treatment so it cannot explain the higher levels of biomarkers found in patients on first-line treatment at baseline. There were four patients who switched to fingolimod from first-line treatment with treatment interruptions of more than 1 year. However, excluding these patients from the analysis did not change the results.
Some of the biomarkers (NFL, 12, 14, 33 GFAP, 12, 27 CHI3L1, 33 and CCL-2 10 ) are age-dependent. However, we made no adjustments for age in the statistical analysis because the HC group was age-matched and the study period was limited to only 4-12 months. Although patients on second-line treatment were of older age, we found no significant increased levels of any of the investigated biomarkers in this group as compared with patients on first-line DMTs, which rather strengthens our results.
In conclusion, our study confirms that CSF biomarkers reflect both disease activity and DMT efficacy. These findings add to those obtained from clinical and MRI measures, since the influence of DMT on CSF biomarkers is selective, that is, different parts of the immunopathogenesis of MS are involved. Fingolimod reduced B-cell activity (CXCL13), markers of glial activation (CHI3L1, CHIT1), and axonal degeneration (NFL) in RRMS patients with breakthrough disease while on first-line DMTs, while the levels of the analyzed biomarkers were essentially unchanged in patients who switched from natalizumab. Interestingly, the reduction in these biomarkers was not confined to MRI activity, which indicate that determination of biomarkers in CSF may add information to those obtained by clinical and MRI measures and may therefore be a measure of treatment efficacy in clinical trials and can also be used for monitoring DMTs in clinical practice.
